Skip to content

Patient-reported outcomes following treatment for localized prostate cancer: helping decision making for patients and their physicians

Research output: Contribution to journalEditorial

Original languageEnglish
Pages (from-to)1121-1123
Number of pages3
JournalJAMA Oncology
Volume317
Issue number11
Early online date21 Mar 2017
DOIs
DateAccepted/In press - 5 Mar 2017
DateE-pub ahead of print - 21 Mar 2017
DatePublished (current) - 21 Mar 2017

Abstract

When treatments are known to be successful with good oncological outcomes for specific cancers, most patients will be prepared to accept the proposed therapy and its consequences on quality of life. But when multiple, equally effective treatments are available and uncertainty about their benefits prevails with a substantial risk of overtreatment, the balance of risks between benefit and harm from adverse effects can dominate decision making. Such is the case in clinically localized prostate-specific antigen (PSA)–detected prostate cancer. Men affected by prostate cancer realize increasingly that survival and prostate cancer recurrence rates alone are insufficient to allow sound clinical decisions to be made and that there are trade-offs between cancer control and adverse treatment effects. Two articles in this issue of JAMA by Barocas and colleagues and by Chen and colleagues address this important problem.

    Structured keywords

  • Centre for Surgical Research

Documents

DOI

View research connections

Related faculties, schools or groups